Cory Renauer
Value, research analyst, biotech, small-cap

Coronado Biosciences Reuniting Old Friends

Coronado Biosciences (CNDO) is zero revenue biotech with two immunotherapy candidates in clinical development. Trichuris suis ova [TSO] or CNDO-201 are the eggs of a parasitic worm that naturally infect pigs, and to a far lesser extent people. CNDO-109 is a biologic that activates the immune system's natural killer cells.

TSO is in varying stages of development for 8 separate indications, of which Chron's disease is most advanced. Although CNDO-109 may have an effect on a variety of cancers, it is currently in Phase 1/2 trials for acute myeloid leukemia, and preclinical stages for Multiple Myeloma.

When good hygiene goes bad

Autoimmune diseases like Crohn's are on the rise nearly everywhere in the developed world. A popular explanation for the...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details